Commentary
Advanced adrenocortical carcinoma: Combination chemotherapy health
Author(s): Vikas Yadav*
Adrenocortical carcinoma has an incidence of 1 per million people and is a rare and aggressive disease. A big tumor's compressive symptoms, hormonal production, or an unintentional finding on imaging tests all contribute to the diagnosis. The best opportunity for a cure is provided via surgery, which has been the basis of treatment. Metastatic disease and local recurrence, however, are frequent. Stage I illness has an 82 percent 5-year survival rate, whereas stage IV disease, which is indicated by distant metastases, has a 13% survival rate. 70% of patients have stage III or stage IV illness when they first arrive. Consequently, a lot of people need systemic treatment. Since 1960, mitotane adjuvant therapy has been the sole authorised treatment for ACC. Patients who have a high risk of recurrence are advised to get adjuvant radiation to the tumour bed. Palliative chemotherapy with.. Read More»
DOI:
10.37532/ puljeds.22.6.3.22-23
+443308089004
